BRIEF published on 09/18/2024 at 07:05, 6 months 15 days ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 6 months 15 days ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 7 months 1 day ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 7 months 1 day ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 7 months 4 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 7 months 4 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 7 months 29 days ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 7 months 29 days ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 9 months 5 days ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 9 months 5 days ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 04/03/2025 at 05:10, 2 hours 48 minutes ago Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 6 hours 23 minutes ago GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 8 hours 23 minutes ago Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 11 hours 58 minutes ago Network-1 Announces Acquisition of Patent Portfolio
Published on 04/03/2025 at 07:30, 28 minutes ago SFC Energy AG receives follow-up order from ZeroAlpha Solutions Ltd on behalf of the NATO Support and Procurement Agency (NSPA)
Published on 04/03/2025 at 07:30, 28 minutes ago ALTUS renewables GmbH places order with Nordex Group for 40 MW in Germany
Published on 04/03/2025 at 07:00, 58 minutes ago AEVIS VICTORIA SA (AEVS.SW) – Publication of the Annual Report 2024
Published on 04/03/2025 at 07:00, 58 minutes ago Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Published on 04/03/2025 at 07:00, 58 minutes ago “Tunnel Ostbahnhof” joint venture awarded contract for eastern section of the Second Core S-Bahn Route in Munich
Published on 04/03/2025 at 00:37, 7 hours 21 minutes ago Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code
Published on 04/02/2025 at 17:45, 14 hours 13 minutes ago Aéroports de Paris SA - Voting rights as of 31 March 2025
Published on 04/02/2025 at 17:45, 14 hours 13 minutes ago Availability of the Pre-Q1 2025 Sales Communication
Published on 04/02/2025 at 17:45, 14 hours 13 minutes ago Information concerning the total number of voting rights and shares 2025 03 31
